Pfizer hires ex-Novartis PR as reputation czar

Share this article:
Pfizer hires ex-Novartis PR as reputation czar
Pfizer hires ex-Novartis PR as reputation czar
Pfizer named Kathryn Metcalfe VP, corporate reputation and policy communication – a new post in which she's tasked with building the company's reputation and communicating Pfizer's stance on policy issues worldwide.

“It's an exciting time to be at Pfizer,” said Metcalfe in a statement. “There is a tangible spirit of change at Pfizer and a strong commitment to the communications function as a strategic driver.”

Metcalfe previously headed communications for Novartis in the US. She joined Novartis in 2004 from the New York office of PR agency Cohn & Wolfe, where she was CEO.

Chief communications officer Sally Sussman called Metcalfe: “a seasoned professional with a proven track record in strategic communications and more than 15 years experience driving significant growth for leading healthcare brands.”
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...